Arikayce (liposomal amikacin) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

this form is Protected freathfr	mormation under meas.		OKGENI
MEMBER INFORMATION			
LAST NAME:		FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	
STREET ADDRESS:	_	1	
CITY:		STATE: ZIP CODE:	
PATIENT INSURANCE ID NUM	ИBER:		
	IBER, YOU WILL NEED TO SUBMIT A PHI DISCL /NOPP RESENTATIVE (IF APPLICABLE)		
PRESCRIBER INFORMATION			
LAST NAME:		FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	
STREET ADDRESS:	_	1	
CITY:		STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:	
		1	
MEDICATION OR MEDICAL I	DISPENSING INFORMATION		
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF	QUANTITY:
		THERAPY/REFILLS:	
NEW THERAPY DURATION OF THERAPY (SPECIFIC DATES):		IF RENEWAL: DATE THERAPY INITIATED:	
	CILIC DATEM.		

Continued on next page.



Arikayce (liposomal amikacin) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

C-positive despite SIX months o lease submit chart documentat	RESPONSE/REASON FOR FAILURE/ALLERGY: ICD-10: CLINICAL INFORMATION TO SUPPORT A of ADHERENT treatment with stable tion of treatment and dates of service. ADHERENT nebulization treatments using a submit chart documentation.
URATION OF THERAPY (SPECIFICATES): ung disease Code(s): LEASE PROVIDE ALL RELEVANT (C-positive despite SIX months of lease submit chart documentate after at least FOUR months of lease) solution? □ Yes □ No Please	RESPONSE/REASON FOR FAILURE/ALLERGY: ICD-10: CLINICAL INFORMATION TO SUPPORT A of ADHERENT treatment with stable tion of treatment and dates of service. ADHERENT nebulization treatments using a submit chart documentation.
LEASE PROVIDE ALL RELEVANT (C-positive despite SIX months of lease submit chart documentate after at least FOUR months of lease) solution? Yes No Please	of ADHERENT treatment with stable tion of treatment and dates of service. ADHERENT nebulization treatments using a submit chart documentation.
LEASE PROVIDE ALL RELEVANT (C-positive despite SIX months of lease submit chart documentate after at least FOUR months of lease) solution? Yes No Please	of ADHERENT treatment with stable tion of treatment and dates of service. ADHERENT nebulization treatments using a submit chart documentation.
C-positive despite SIX months o lease submit chart documentat after at least FOUR months of A us) solution? Yes No Please	of ADHERENT treatment with stable tion of treatment and dates of service. ADHERENT nebulization treatments using a submit chart documentation.
lease submit chart documentate after at least FOUR months of Aus) solution? Yes No Please	tion of treatment and dates of service. ADHERENT nebulization treatments using submit chart documentation.
s the use of multi-drug regimens th drugs include macrolides (clarithro	Please submit chart documentation. hat are not specifically approved for omycin or azithromycin), ethambutol, and amikacin, are also used as additional
	cure turned MAC-negative by month #6 after
es, symptoms, medications trie w?	d or failed, and/or any other information the
	the use of multi-drug regimens the drugs include macrolides (clarithreflycosides, such as streptomycin and ation that patient's sputum cult efits coverage



Arikayce (liposomal amikacin) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.		
Prescriber Signature or Electronic I.D. Verification:	Date:	
you are not the intended recipient, you are hereby notified that any	mission contain confidential health information that is legally privileged. If disclosure, copying, distribution, or action taken in reliance on the contents formation in error, please notify the sender immediately (via return FAX)	

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

